Reta glucagon-like peptide-1 (GLP-1) receptor agonists offer a groundbreaking method to diabetes management. These innovative therapies operate by mimicking the physiological actions of GLP-1, a hormone released by the gut in response to meals. By triggering GLP-1 receptors in the pancreas, these substances enhance insulin production and inhibit gl

The management of diabetes is with the emergence of exciting new therapies. Among these, Reta, GLP-1 receptor agonists, Retatrutide, and Trizepatide are gaining significant recognition. These medications offer promising strategies for controlling blood sugar levels and could improve the lives of individuals living with diabetes. This novel class